ArticleAdvanced healthcare materials2026
Functional Blood-Brain Barrier Crossing by Biomimetic M13 Phage Vectors for Targeted Neuronal Delivery.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The blood-brain barrier (BBB) is a highly selective gatekeeper. While providing essential protection against pathogens, BBB also poses a major challenge by restricting the delivery of systemically administered therapeutics. Consequently, there is a pressing need for innovative strategies that can efficiently and selectively target neuronal populations to treat diverse brain disorders. Nanomaterials enable transcellular transport across the endothelial layer; however, given the biomolecular corona paradigm, designing biomimetic hybrid nanoconstructs that preserve and leverage biological functionality within a complex physiological environment is more promising. Here, we investigated the potential of M13 bacteriophages as biocompatible and versatile nanovectors across the BBB. M13 phages exhibited: (i) a high cargo capacity within the main protein capsomer (here exploited for fluorescent labeling); (ii) offered genetic flexibility for ligand display; (iii) showed a natural propensity to efficiently cross the endothelial layer via specific intracellular pathways; (iv) maintained their structure and functionality intact. We also demonstrate that M13 phages engineered to target specific neuronal populations via single-domain antibody display retain their specificity after BBB translocation and in a protein- and cell-crowded environment. Overall, our results provide mechanistic insights emphasizing an unprecedented field of application for (engineered) M13 phages as biomimetic nanotools for targeting and delivery across the BBB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.